歌礼制药-B早盘涨超21% 礼来公布口服降糖药取得积极结果

金融界
22 Apr

歌礼制药-B早盘上涨21.46%,现报6港元,成交额2550.55万港元。

4月14日,辉瑞因潜在肝损伤终止开发GLP-1小分子受体激动剂Danuglipron。4月17日,礼来宣布口服药Orforglipron的III期ACHIEVE-1研究取得积极顶线结果,在糖化血红蛋白管理、体重控制和安全性方面均与注射剂型相仿,即将申报上市。

责任编辑:栎树

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10